Integra LifeSciences Launches Veterinary Orthopedic Implants
PLAINSBORO, N.J., March 15, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corp (Nasdaq:IART) today announced the launch of the Integra® Miltex® Veterinary Orthopedic Implant line, which includes plates, screws, lateral suturing products and instruments that aid in the repair of torn cruciate ligaments and broken or fractured bones in companion animals. Integra currently offers veterinarians a full line of instruments, which are vital to running a successful practice.
"As a leader in the Animal Health market, veterinarians have come to depend on the quality of Integra Miltex for both dental and surgical instruments. The addition of orthopedic implants is a natural extension of our portfolio, and provides an ideal complement to our orthopedic instruments," said Dan Reuvers, President, Integra Instruments.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of veterinary professionals to use the products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com